Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CCNK | O75909 | 1/20 | 0.56 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643920 | 0.80 | MEN1 (0.58) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL26618971 | 0.80 | MEN1 (0.58) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL27939486 | 0.79 | MEN1 (0.60) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL16833928 | 0.79 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL13728011 | 0.75 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL25224063 | 0.75 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9AHSP90AA1 | |
| SCHEMBL28330051 | 0.74 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AHSP90AA1 | |
| SCHEMBL26619001 | 0.74 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL29094364 | 0.73 | MEN1 (0.58) | MEN1KMT2ANPC1RAB9ACCNK | |
| SCHEMBL19026569 | 0.73 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MEN1 4876/4885KMT2A 1532/4885NPC1 4448/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | MEN1 4876/4885KMT2A 1532/4885NPC1 4448/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MEN1 4876/4885KMT2A 1532/4885NPC1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.